Pacific Biosciences Of California (PACB) Shareholder's Equity Growth (3y) (2013 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Pacific Biosciences Of California | 481.66 Mn | 205.70 Mn | 12.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -84.94% |
| Dec 31, 2025 | -78.82% |
| Sep 30, 2025 | -61.38% |
| Jun 30, 2025 | -55.16% |
| Mar 31, 2025 | -50.03% |
| Dec 31, 2024 | -13.80% |
| Jun 30, 2024 | 24.03% |
| Mar 31, 2024 | 32.26% |
| Dec 31, 2023 | 27.86% |
| Sep 30, 2023 | 80.67% |
| Jun 30, 2023 | 149.39% |
| Mar 31, 2023 | 125.44% |
| Dec 31, 2022 | 117.22% |
| Sep 30, 2022 | 130.73% |
| Jun 30, 2022 | 108.02% |
| Mar 31, 2022 | 97.85% |
| Dec 31, 2021 | 90.70% |
| Jun 30, 2021 | 44.57% |
| Mar 31, 2021 | 39.77% |
| Dec 31, 2020 | 57.36% |
| Sep 30, 2020 | 8.49% |
| Jun 30, 2020 | -29.04% |
| Mar 31, 2020 | -4.42% |
| Dec 31, 2019 | -13.44% |
| Sep 30, 2019 | -19.74% |
| Jun 30, 2019 | -11.17% |
| Mar 31, 2019 | 2.23% |
| Dec 31, 2018 | 15.75% |
| Sep 30, 2018 | 47.17% |
| Jun 30, 2018 | 36.19% |
| Mar 31, 2018 | 36.41% |
| Dec 31, 2017 | 16.15% |
| Sep 30, 2017 | 24.12% |
| Jun 30, 2017 | 25.22% |
| Mar 31, 2017 | -2.88% |
| Dec 31, 2016 | 6.97% |
| Sep 30, 2016 | 5.71% |
| Jun 30, 2016 | 2.48% |
| Dec 31, 2015 | -12.40% |
| Mar 31, 2015 | -37.77% |
| Dec 31, 2014 | -34.04% |
| Sep 30, 2014 | -36.86% |
| Jun 30, 2014 | -36.76% |
| Dec 31, 2013 | -37.24% |